Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835339 | 0.89 | GHSR (0.47) | GHSRKCNH2ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835272 | 0.82 | GHSR (0.67) | GHSRKCNH2ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835049 | 0.75 | GHSR (0.46) | GHSRKCNH2ATMSMN1; SMN2OPRM1 | |
| SCHEMBL5835216 | 0.74 | GHSR (0.77) | GHSRKCNH2ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5836521 | 0.73 | GHSR (0.64) | GHSRSMN1; SMN2ALDH1A1TSHRDRD2 | |
| SCHEMBL15218847 | 0.69 | GHSR (0.41) | GHSRKCNH2OPRM1OPRD1OPRL1 | |
| SCHEMBL5835557 | 0.68 | GHSR (0.70) | GHSRKCNH2ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835274 | 0.67 | GHSR (0.65) | GHSRALDH1A1DRD2 | |
| SCHEMBL9527330 | 0.67 | TACR1 (0.40) | GHSRATMSMN1; SMN2 | |
| SCHEMBL5836256 | 0.65 | GHSR (0.69) | GHSRKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885KCNH2 3931/4885ATM 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.